SAGE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.69 USD | +0.81% |
|
+2.70% | -36.83% |
| Apr. 25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
| Apr. 25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,741 | 4,502 | 2,506 | 2,269 | 1,301 | 823.9 | - | - |
| Enterprise Value (EV) 1 | 2,732 | 2,841 | 763.7 | 996.6 | 547.7 | 294.3 | 487.2 | 350.6 |
| P/E ratio | -5.4 x | 7.57 x | -5.45 x | -4.25 x | -2.39 x | -2.06 x | -2.72 x | -4.53 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 545 x | 4.04 x | 397 x | 295 x | 15 x | 21.5 x | 5.96 x | 2.49 x |
| EV / Revenue | 398 x | 2.55 x | 121 x | 130 x | 6.34 x | 7.68 x | 3.53 x | 1.06 x |
| EV / EBITDA | -3.87 x | 4.53 x | -1.67 x | -1.83 x | -0.95 x | -0.66 x | -1.18 x | -0.95 x |
| EV / FCF | -5.11 x | 4.3 x | -2.02 x | -2.16 x | -1.01 x | -0.93 x | -2.33 x | -11.8 x |
| FCF Yield | -19.6% | 23.3% | -49.6% | -46.3% | -98.8% | -108% | -42.9% | -8.44% |
| Price to Book | 3.96 x | 2.43 x | 1.45 x | 1.81 x | 1.63 x | 1.68 x | 1.35 x | 0.8 x |
| Nbr of stocks (in thousands) | 51,818 | 52,045 | 58,908 | 59,494 | 60,033 | 60,182 | - | - |
| Reference price 2 | 72.19 | 86.51 | 42.54 | 38.14 | 21.67 | 13.69 | 13.69 | 13.69 |
| Announcement Date | 2/27/20 | 2/24/21 | 2/24/22 | 2/16/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.868 | 1,114 | 6.308 | 7.686 | 86.46 | 38.31 | 138.2 | 330.3 |
| EBITDA 1 | -705.8 | 626.6 | -456.7 | -545.9 | -578.5 | -445.7 | -414.5 | -369.5 |
| EBIT 1 | -708.1 | 624 | -460.9 | -547 | -579.8 | -432 | -342.4 | -204.9 |
| Operating Margin | -10,310.48% | 56% | -7,306.74% | -7,116.69% | -670.69% | -1,127.72% | -247.87% | -62.05% |
| Earnings before Tax (EBT) 1 | -680.2 | 606.1 | -457.9 | -532.8 | -541.5 | -401.2 | -317.3 | -169.2 |
| Net income 1 | -680.2 | 606.1 | -457.9 | -532.8 | -541.5 | -399 | -324.7 | -194.7 |
| Net margin | -9,904.46% | 54.4% | -7,258.91% | -6,931.88% | -626.32% | -1,041.49% | -235.06% | -58.95% |
| EPS 2 | -13.38 | 11.43 | -7.800 | -8.980 | -9.050 | -6.634 | -5.039 | -3.023 |
| Free Cash Flow 1 | -534.5 | 660.8 | -378.6 | -461 | -541.1 | -318.1 | -209.1 | -29.6 |
| FCF margin | -7,781.84% | 59.31% | -6,001.17% | -5,997.57% | -625.92% | -830.48% | -151.33% | -8.96% |
| FCF Conversion (EBITDA) | - | 105.46% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 109.03% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 2/24/22 | 2/16/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.642 | 1.582 | 1.501 | 1.739 | 2.865 | 3.294 | 2.474 | 2.716 | 77.97 | 7.902 | 8.288 | 10.09 | 12.21 | 30.86 | 48.94 |
| EBITDA | -125.2 | -119.4 | -125.5 | -140.1 | -153.6 | -158.3 | -174.5 | -182.9 | -35.48 | - | - | - | - | - | - |
| EBIT 1 | -125.5 | -123.2 | -128.4 | -141.5 | -153.9 | -155.5 | -170.5 | -178.2 | -42.07 | -117.7 | -109.2 | -107.6 | -103.5 | -86.1 | -61.99 |
| Operating Margin | -7,642.33% | -7,787.55% | -8,554.76% | -8,135.71% | -5,371.8% | -4,719.79% | -6,889.94% | -6,562.96% | -53.96% | -1,489.18% | -1,317.82% | -1,067.12% | -847.48% | -279% | -126.66% |
| Earnings before Tax (EBT) 1 | -124.7 | -122.1 | -126.3 | -137.3 | -147.1 | -146.8 | -160.3 | -201.6 | -32.71 | -108.5 | -99.04 | -97.26 | -94.72 | -63.57 | -54.82 |
| Net income 1 | -124.7 | -122.1 | -126.3 | -137.3 | -147.1 | -146.8 | -160.3 | -201.6 | -32.71 | -108.5 | -98.89 | -97.65 | -95.27 | -63.57 | -54.82 |
| Net margin | -7,595.13% | -7,715.23% | -8,411.73% | -7,896.66% | -5,135.99% | -4,457.44% | -6,480.4% | -7,423.78% | -41.95% | -1,372.85% | -1,193.11% | -968.19% | -780.38% | -206% | -112.02% |
| EPS 2 | -2.120 | -2.070 | -2.130 | -2.310 | -2.470 | -2.460 | -2.680 | -3.370 | -0.5500 | -1.800 | -1.631 | -1.602 | -1.572 | -1.430 | -1.177 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/3/22 | 8/2/22 | 11/8/22 | 2/16/23 | 5/2/23 | 8/7/23 | 11/7/23 | 2/14/24 | 4/25/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,008 | 1,661 | 1,742 | 1,272 | 753 | 530 | 337 | 473 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -534 | 661 | -379 | -461 | -541 | -318 | -209 | -29.6 |
| ROE (net income / shareholders' equity) | -75.3% | 42% | -24.1% | -35.7% | -49.5% | -58.1% | -29.4% | -2.69% |
| ROA (Net income/ Total Assets) | -66.8% | 39.1% | -23% | -33.5% | -45.4% | -59.9% | -26.9% | -6.76% |
| Assets 1 | 1,018 | 1,551 | 1,992 | 1,591 | 1,193 | 665.7 | 1,208 | 2,881 |
| Book Value Per Share 2 | 18.20 | 35.50 | 29.30 | 21.00 | 13.30 | 8.160 | 10.20 | 17.00 |
| Cash Flow per Share 2 | -10.40 | 12.50 | -6.450 | -7.760 | -9.030 | -4.930 | -3.560 | -0.6300 |
| Capex 1 | 5.75 | 0.35 | 0.37 | 0.94 | 0.55 | 1.81 | 3.01 | 3.11 |
| Capex / Sales | 83.74% | 0.03% | 5.9% | 12.19% | 0.64% | 4.73% | 2.18% | 0.94% |
| Announcement Date | 2/27/20 | 2/24/21 | 2/24/22 | 2/16/23 | 2/14/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
13.69
USD
Average target price
22.67
USD
Spread / Average Target
+65.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.83% | 824M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
- Financials Sage Therapeutics, Inc.
